Eli Lilly Faces Competitive Pressure as Novo Nordisk Launches GLP-1 Pill
Eli Lilly leads the GLP-1 drug market with Mounjaro and Zepbound, but Novo Nordisk's new pill version and high valuation raise investor concerns.
Topic
Latest reporting and analysis tagged with pharmaceutical competition.
Eli Lilly leads the GLP-1 drug market with Mounjaro and Zepbound, but Novo Nordisk's new pill version and high valuation raise investor concerns.